EBAG9
EBAG9 (oestrogen receptor binding site associated antigen 9) is an oestrogen-responsive gene whose product is a tumour-associated antigen, also known as RCAS1, EB9 and PDAF. The protein is a Golgi membrane protein linked to suppression of cell proliferation and apoptotic cell death. Browse Assay Genie's current range of EBAG9 research reagents below, or read on for the biology behind the target.
EBAG9 is a protein that may participate in the suppression of cell proliferation. According to UniProt, it induces apoptotic cell death through activation of interleukin-1-beta converting enzyme (ICE)-like proteases. The UniProt protein name, receptor-binding cancer antigen expressed on SiSo cells, reflects its identification as a cancer-associated antigen, and the protein is localised to the Golgi apparatus membrane.
The EBAG9 gene was identified as an oestrogen-responsive gene. Transcriptional regulation by oestrogen is mediated by the oestrogen receptor, which binds to the oestrogen-responsive element in the 5'-flanking region of the gene. This origin gives the gene its full name, oestrogen receptor binding site associated antigen 9. Alternate splicing results in multiple transcript variants, and a pseudogene has been defined on chromosome 10.
The encoded protein is a tumour-associated antigen that is expressed at high frequency in a variety of cancers. This makes EBAG9, also called RCAS1, EB9 or PDAF, a point of interest for researchers studying hormone-responsive gene regulation, tumour antigen biology and apoptosis. Orthologous Ebag9 genes are recorded in mouse and rat, so the target can be studied in common rodent models.
EBAG9 is a tumour-associated antigen expressed at high frequency in a variety of cancers, making it a subject of tumour research.
EBAG9 may induce apoptotic cell death through activation of ICE-like proteases, linking it to cell death pathways.
The protein may participate in suppression of cell proliferation, a function relevant to growth regulation studies.
The gene is regulated by oestrogen receptor binding to an oestrogen-responsive element in its 5'-flanking region.
EBAG9 may participate in suppression of cell proliferation and induce apoptotic cell death through activation of interleukin-1-beta converting enzyme (ICE)-like proteases. It is also a tumour-associated antigen expressed at high frequency in a variety of cancers, and it localises to the Golgi apparatus membrane.
EBAG9 is also known as RCAS1, EB9 and PDAF. UniProt names the protein receptor-binding cancer antigen expressed on SiSo cells. The HGNC full name is oestrogen receptor binding site associated antigen 9. Alternate splicing gives multiple transcript variants.
Yes. Mouse and rat both have an orthologous gene named Ebag9. The human gene was identified as oestrogen-responsive, and a pseudogene exists on chromosome 10. Check the datasheet of any product for its validated reactivity.
Estrogen receptors, ICE-like proteases and apoptosis-pathway targets related to EBAG9 biology.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O00559; product specifications from Assay Genie datasheets.